U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07328217) titled 'A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors' on Dec. 26, 2025.
Brief Summary: This is a phase 1/2, open-label, multicenter study assessing the safety, tolerability, pharmacokinetics and efficacy of GW5282 in participants with locally advanced or metastatic solid tumors. This study comprised of a dose escalation phase to determine the MTD and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of GW5282.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: GW5282
Single dose period (only for dose escalation phase):...